CoChat
Sign Up
Cited by 126Nanoparticle-Based Drug DeliveryMesenchymal stem cell researchCancer Research and Treatments

Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system

Open access
Wang, Xusheng, Chen, Haiyan, Zeng, Xiaowei, Guo, Wenpeng, Jin, Yu, Wang, Shan, Tian, Ruiyun, Han, Yanjiang +4 more·2019·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2018.08.006PMC PMC6362298
Open this paper in CoChat — free account

Abstract

Low targeting efficiency limits the applications of nanoparticles in cancer therapy. The fact that mesenchymal stem cells (MSC) trapped in the lung after systemic infusion is a disadvantage for cell therapy purposes. Here, we utilized MSC as lung cancer-targeted drug delivery vehicles by loading nanoparticles (NP) with anti-cancer drug. MSC showed a higher drug intake capacity than fibroblasts. In addition, MSC showed predominant lung trapping in both rabbit and monkey. IR-780 dye, a fluorescent probe used to represent docetaxel (DTX) in NP, delivered via MSC accumulated in the lung. Both in vitro MSC/A549 cell experiments and in vivo MSC/lung cancer experiments validated the intercellular transportation of NP between MSC and cancer cells. In vivo assays showed that the MSC/NP/DTX drug delivery system exerted primary tumor inhibition efficiency similar to that of a NP/DTX drug system. Collectively, the MSC/NP drug delivery system is promising for lung-targeted drug delivery for the treatment of lung cancer and other lung-related diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2018.08.006

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both BM-MSCs and ASCs have the ability to take up certain anti-cancer agents using three main mechanisms: transporters, simple diffusion, and endocytosis.

    “Both BM-MSCs and ASCs have the ability to take up certain anti-cancer agents using three main mechanisms: transporters, simple diffusion, and endocytosis.”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [112]

    The Results section, “MSC have great capacity in nanoparticle/drug intake” (page not provided), reports anticancer-drug uptake by MSCs and increased clathrin expression, consistent with a role for endocytosis. The paper does not establish uptake by ASCs or identify transporters, simple diffusion, and endocytosis as three main uptake mechanisms. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • ASCs show increased levels of the endocytosis mediator clathrin, which may play a role in the internalization of drugs via receptor-mediated endocytosis.

    “ASCs also show increased levels of the endocytosis mediator clathrin, which may play a role in the internalization of drugs via receptor-mediated endocytosis [109,112].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [112]

    The Results section, “MSC have great capacity in nanoparticle/drug intake” (page unavailable), reports increased clathrin expression in MSC and identifies clathrin as an endocytosis mediator. But the Methods section, “Cell culture, 3D cell spheres and cell imaging” (page unavailable), says these MSC were isolated from placenta, not adipose tissue; the paper also does not identify receptor-mediated endocytosis as the route of drug uptake. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. [2]Zhang M. Kim Y.K. Cui P.F. Zhang J.L. Qiao J.B. He Y.J. Folate-conjugated polyspermine for lung cancer-targeted gene therapy Acta Pharm Sin B 6 2016 336 343 27471674 PMC4951589
  2. [5]Qiao L. Xu Z. Zhao T. Zhao Z. Shi M. Zhao R.C. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model Cell Res 18 2008 500 507 18364678
  3. [6]Lee M. Jeong S.Y. Ha J. Kim M. Jin H.J. Kwon S.J. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo Biochem Biophys Res Commun 446 2014 983 989 24657442
  4. [8]Zhao Y. Tang S. Guo J. Alahdal M. Cao S. Yang Z. Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy Sci Rep 7 2017 44758 28303966 PMC5355993
  5. [9]Gao J. Dennis J.E. Muzic R.F. Lundberg M. Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion Cells Tissues Organs 169 2001 12 20 11340257
  6. [10]Barbash I.M. Chouraqui P. Baron J. Feinberg M.S. Etzion S. Tessone A. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution Circulation 108 2003 863 868 12900340
  7. [11]Bos J.L. Ras oncogenes in human cancer—a review Cancer Res 49 1989 4682 4689 2547513
  8. [12]Avruch J. Zhang X.F. Kyriakis J.M. Raf meets Ras—completing the framework of a signal-transduction pathway Trends Biochem Sci 19 1994 279 283 8048167
  9. [13]Khosravifar R. Der C.J. The Ras signal transduction pathway Cancer Metastas- Rev 13 1994 67 89 8143346
  10. [14]Mills N.E. Fishman C.L. Rom W.N. Dubin N. Jacobson D.R. Increased prevalence of K-Ras oncogene mutations in lung adenocarcinoma Cancer Res 55 1995 1444 1447 7882350
  11. [15]Pellegata N.S. Sessa F. Renault B. Bonato M. Leone B.E. Solcia E. K-Ras and p53 gene-mutations in pancreatic-cancer—ductal and nonductal tumors progress through different genetic lesions Cancer Res 54 1994 1556 1560 8137263
  12. [16]Pessina A. Piccirillo M. Mineo E. Catalani P. Gribaldo L. Marafante E. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM) Life Sci 65 1999 513 523 10462078
  13. [17]Pascucci L. Cocce V. Bonomi A. Ami D. Ceccarelli P. Ciusani E. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery J Control Release 192 2014 262 270 25084218
  14. [18]Cocce V. Farronato D. Brini A.T. Masia C. Gianni A.B. Piovani G. Drug loaded gingival mesenchymal stromal cells (GinPa-MSCs) inhibit in vitro proliferation of oral squamous cell carcinoma Sci Rep 7 2017 9376 28839168 PMC5571047
  15. [19]Le Blanc K. Rasmusson I. Sundberg B. Gotherstrom C. Hassan M. Uzunel M. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 363 2004 1439 1441 15121408
  16. [20]Horwitz E.M. Prockop D.J. Fitzpatrick L.A. Koo W.W. Gordon P.L. Neel M. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta Nat Med 5 1999 309 313 10086387
  17. [22]Prockop D.J. Marrow stromal cells as stem cells for continual renewal of nonhematopoietic tissues and as potential vectors for gene therapy J Cell Biochem 72 1998 S284 S285 29345820
  18. [23]Dezawa M. Ishikawa H. Itokazu Y. Yoshihara T. Hoshino M. Takeda S. Bone marrow stromal cells generate muscle cells and repair muscle degeneration Science 309 2005 314 317 16002622
  19. [24]Pittenger M.F. Mackay A.M. Beck S.C. Jaiswal R.K. Douglas R. Mosca J.D. Multilineage potential of adult human mesenchymal stem cells Science 284 1999 143 147 10102814
  20. [25]Squillaro T. Peluso G. Galderisi U. Clinical trials with mesenchymal stem cells: an update Cell Transplant 25 2016 829 848 26423725
  21. [26]Giordano A. Galderisi U. Marino I.R. From the laboratory bench to the patients bedside: an update on clinical trials with mesenchymal stem cells J Cell Physiol 211 2007 27 35 17226788
  22. [27]Bartolucci J. Verdugo F.J. Larrea R. Abarzua E. Goset C. Rojo P. Phase 1/2 randomized clinical trial of intravenous infusion of umbilical cord mesenchymal stem cells in patients with chronic cardiopathy with stable heart failure (RIMECARD) Eur Heart J 37 2016 527 PMC6372053 28974553
  23. [28]Zhu H.B. Cao B.R. Zhen Z.P. Laxmi A.A. Li D. Liu S.R. Controlled growth and differentiation of MSCs on grooved films assembled from monodisperse biological nanofibers with genetically tunable surface chemistries Biomaterials 32 2011 4744 4752 21507480 PMC3099180
  24. [29]Sonabend A.M. Ulasov I.V. Tyler M.A. Rivera A.A. Mathis J.M. Lesniak M.S. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma Stem Cells 26 2008 831 841 18192232
  25. [30]Kidd S. Spaeth E. Dembinski J.L. Dietrich M. Watson K. Klopp A. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging Stem Cells 27 2009 2614 2623 19650040 PMC4160730
  26. [31]Dwyer R.M. Potter-Beirne S.M. Harrington K.A. Lowery A.J. Hennessy E. Murphy J.M. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells Clin Cancer Res 13 2007 5020 5027 17785552
  27. [32]Jang S.C. Kim O.Y. Yoon C.M. Choi D.S. Roh T.Y. Park J. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors ACS Nano 7 2013 7698 7710 24004438
  28. [33]Rani S. Ryan A.E. Griffin M.D. Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications Mol Ther 23 2015 812 823 25868399 PMC4427881

Cited by

Sorted by citations

Authors
Wang, X., Chen, H., Zeng, X., Guo, W., Jin, Y., Wang, S., Tian, R., Han, Y., Guo, L., Han, J., Wu, Y., & Mei, L.
Affiliations
  • Sun Yat-sen University (CN)
  • Tsinghua–Berkeley Shenzhen Institute (CN)
  • Shenzhen University (CN)
  • Tsinghua University (CN)
  • Nanfang Hospital (CN)
  • Southern University of Science and Technology (CN)
Corresponding author
  • Wu, Yaojiong
  • Mei, Lin
ORCID
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2019-01
Volume
9
Issue
1
Pages
167-176
ISSN
2211-3835 (ISSN-L)
DOI
10.1016/j.apsb.2018.08.006
PMC
PMC6362298
OpenAlex
W2890037297
Cited by
126
References
3
Citations by year
2026: 6 · 2025: 9 · 2024: 18 · 2023: 26 · 2022: 16 · 2021: 16 · 2020: 28 · 2019: 6 · 2018: 1
FWCI
4.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of China (81771966, 31371404, 31401187, 31571429)
  • Fundamental Research Funds for the Central Universities
  • Guangdong Natural Science Funds for Distinguished Young Scholar (2014A030306036)
  • Natural Science Foundation of Guangdong, China (2015A030311041, 2015A030313763)
  • Science and Technology Planning Project of Guangdong Province, China (2016A020217001, 2014A020212466)
  • Shenzhen Science and Technology InnovationCommittee (JCYJ20160301152300347, JCYJ20160531195129079, JCYJ20170412095722235, JCYJ2016042-9171931438, GJHZ20150316160614842)
  • Guangdong Province Medical Science and Technology Research Fund (A2016445)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
Keywords
lung cancer, targeted drug delivery, mesenchymal stem cells, nanoparticles, docetaxel, IR780, A549 cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review